Literature DB >> 22796116

Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients.

H Segers1, R Kersseboom, M Alders, R Pieters, A Wagner, M M van den Heuvel-Eibrink.   

Abstract

INTRODUCTION: In 9-17% of Wilms tumour patients a predisposing syndrome is present, in particular WT1-associated syndromes and overgrowth syndromes. Constitutional WT1 mutations or epigenetic changes on chromosome 11p15 have also been described in Wilms tumour patients without phenotypic abnormalities. Thus, the absence of phenotypic abnormalities does not exclude the presence of a genetic predisposition, suggesting that more Wilms tumour patients may have a constitutional abnormality. Therefore, we investigated the frequency of constitutional aberrations in combination with phenotype. PATIENTS &
METHODS: Clinical genetic assessment, as well as molecular analysis of WT1 and locus 11p15 was offered to a single-centre cohort of 109 childhood Wilms tumour patients.
RESULTS: Twelve patients (11%) had a WT1 aberration and eight patients (8%) had an 11p15 aberration. Of the 12 patients with a WT1 aberration, four had WAGR syndrome (Wilms tumor, aniridia, genitourinary malformations and mental retardation), one had Denys-Drash syndrome, four had genitourinary anomalies without other syndromic features and three had bilateral disease with stromal-predominant histology at young age without congenital anomalies. Of the eight patients with an 11p15 aberration, four had Beckwith-Wiedemann syndrome (BWS), two had minor features of BWS and two had no stigmata of BWS or hemihypertrophy.
CONCLUSION: Constitutional WT1 or 11p15 aberrations are frequent in Wilms tumour patients and careful clinical assessment can identify the majority of these patients. Therefore, we would recommend offering clinical genetic counselling to all Wilms tumour patients, as well as molecular analysis to patients with clinical signs of a syndrome or with features that may indicate a constitutional WT1 or 11p15 aberration.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22796116     DOI: 10.1016/j.ejca.2012.06.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

Review 1.  A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.

Authors:  Sarah Scollon; Amanda Knoth Anglin; Martha Thomas; Joyce T Turner; Kami Wolfe Schneider
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

Review 2.  [Tumor predisposition syndromes and nephroblastoma : Early diagnosis with imaging].

Authors:  N Welter; R Furtwängler; G Schneider; N Graf; J-P Schenk
Journal:  Radiologie (Heidelb)       Date:  2022-08-25

3.  Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor.

Authors:  Dinesh Kumar Sahu; Neetu Singh; Mumani Das; Jiledar Rawat; Devendra Kumar Gupta
Journal:  Pediatr Surg Int       Date:  2022-09-15       Impact factor: 2.003

4.  The effectiveness of Wilms tumor screening in Beckwith-Wiedemann spectrum.

Authors:  Alessandro Mussa; Kelly A Duffy; Diana Carli; Jessica R Griff; Riccardo Fagiano; Jonida Kupa; Garrett M Brodeur; Giovanni Battista Ferrero; Jennifer M Kalish
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-04       Impact factor: 4.553

Review 5.  Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.

Authors:  Jennifer M Kalish; Leslie Doros; Lee J Helman; Raoul C Hennekam; Roland P Kuiper; Saskia M Maas; Eamonn R Maher; Kim E Nichols; Sharon E Plon; Christopher C Porter; Surya Rednam; Kris Ann P Schultz; Lisa J States; Gail E Tomlinson; Kristin Zelley; Todd E Druley
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

6.  Diagnosis of Beckwith-Wiedemann syndrome in children presenting with Wilms tumor.

Authors:  Suzanne P MacFarland; Kelly A Duffy; Tricia R Bhatti; Rochelle Bagatell; Naomi J Balamuth; Garrett M Brodeur; Arupa Ganguly; Peter A Mattei; Lea F Surrey; Frank M Balis; Jennifer M Kalish
Journal:  Pediatr Blood Cancer       Date:  2018-06-22       Impact factor: 3.167

7.  A high incidence of WT1 abnormality in bilateral Wilms tumours in Japan, and the penetrance rates in children with WT1 germline mutation.

Authors:  Y Kaneko; H Okita; M Haruta; Y Arai; T Oue; Y Tanaka; H Horie; S Hinotsu; T Koshinaga; A Yoneda; Y Ohtsuka; T Taguchi; M Fukuzawa
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

8.  The IGF signalling pathway in Wilms tumours--a report from the ENCCA Renal Tumours Biology-driven drug development workshop.

Authors:  Mariana Maschietto; Jocelyn Charlton; Daniela Perotti; Paolo Radice; James I Geller; Kathy Pritchard-Jones; Mark Weeks
Journal:  Oncotarget       Date:  2014-09-30

9.  Phenotypic characterization of patients with early-onset high myopia due to mutations in COL2A1 or COL11A1: Why not Stickler syndrome?

Authors:  Lin Zhou; Xueshan Xiao; Shiqiang Li; Xiaoyun Jia; Panfeng Wang; Wenmin Sun; Fengsheng Zhang; Jiazhang Li; Tuo Li; Qingjiong Zhang
Journal:  Mol Vis       Date:  2018-08-10       Impact factor: 2.367

Review 10.  Genetic Predisposition to Solid Pediatric Cancers.

Authors:  Mario Capasso; Annalaura Montella; Matilde Tirelli; Teresa Maiorino; Sueva Cantalupo; Achille Iolascon
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.